Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Amylyx Pharmaceuticals Inc AMLX

Healthcare
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral... see more

Recent & Breaking News (NDAQ:AMLX)

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Amylyx

Newsfile April 6, 2024

FINAL DEADLINE TUESDAY: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire April 6, 2024

AMYLYX PHARMACEUTICALS 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX

Business Wire April 5, 2024

AMLX FINAL DEADLINE: TOP RANKED ROSEN LAW FIRM Encourages Amylyx Pharmaceuticals, Inc. Investors to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX

Newsfile April 5, 2024

Investors in Amylyx Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before April 9, 2024 to Discuss Your Rights - AMLX

Accesswire April 5, 2024

AMLX Investors Have Opportunity to Lead Amylyx Pharmaceuticals, Inc. Securities Fraud Lawsuit

PR Newswire April 5, 2024

Amylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint - Hagens Berman

Newsfile April 5, 2024

Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (AMLX) as Company Formally Pulls Relyvrio from the Market

Newsfile April 5, 2024

Investors Who Lost Money on Amylyx Pharmaceuticals, Inc.(AMLX) Should Contact Levi & Korsinsky About Pending Class Action - AMLX

Accesswire April 5, 2024

FINAL DEADLINE IMMINENT: The Schall Law Firm Encourages Investors in Amylyx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Accesswire April 5, 2024

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AMLX

PR Newswire April 5, 2024

Investors who lost money on Amylyx Pharmaceuticals, Inc. (AMLX) should contact Levi & Korsinsky about pending Class Action - AMLX

Accesswire April 5, 2024

IMMINENT AMLX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Amylyx Pharmaceuticals, Inc. Investors to Join the Class Action Lawsuit!

Accesswire April 5, 2024

Class Action Filed Against Amylyx Pharmaceuticals, Inc. (AMLX) Seeking Recovery for Investors - Contact Levi & Korsinsky

Accesswire April 4, 2024

AMYLYX PHARMACEUTICALS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. - AMLX

Accesswire April 4, 2024

AMLX FINAL DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Amylyx Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 9 Deadline in Securities Class Action - AMLX

PR Newswire April 4, 2024

Amylyx Pharmaceuticals, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - AMLX

Accesswire April 4, 2024

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of April 9, 2024 in Amylyx Lawsuit - AMLX

Accesswire April 4, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - AMLX

PR Newswire April 4, 2024

Amylyx Pharmaceuticals Sued for Securities Law Violations; Investors Should Contact Block & Leviton for More Information

Accesswire April 4, 2024